Background: Type 1 regulatory T (Tr1) cells, characterized by the secretion of high levels of the anti-inflammatory cytokine interleukin-10 (IL-10), play an important role in the regulation of autoimmune diseases and transplantation. However, effective strategies that specifically induce Tr1 cells in vivo are limited. Furthermore, the pathways controlling the induction of these cells in vivo are not well understood.
Introduction
The generation of functional regulatory T cells in vivo is a major goal for the treatment of immune-mediated diseases. Tr1 cells are regulatory T cells characterized by a cytokine profile that is distinct from T helper 1 (Th1), Th2, Th3 and Foxp3+ regulatory T cells (Treg) [1] . Tr1 cells do not constitutively express the transcription factor forkhead box p3 (Foxp3), which is a lineage specific marker for both naturally occurring and induced CD4+CD25+ regulatory T cells [2] . Upon T-cell receptor (TCR) mediated activation, Tr1 cells produce high levels of IL-10 and transforming growth factor-beta (TGF-b), low levels of interferon-gamma (IFN-c) and almost no IL-2 or IL-4.
The mechanism of in vitro suppression by Tr1 cells is linked to IL-10 [3, 4] as neutralization of IL-10 by monoclonal antibodies typically reverses suppression. Upon TCR stimulation, Tr1 cells can mediate bystander suppression by the local release of IL-10 and TGF-b that act on both antigen presenting cells (APCs) and T cells to suppress co-stimulatory molecule expression and proinflammatory cytokine production, respectively [5] .
Tr1 cells can be generated in vitro from naïve precursors in response to different cytokine milieus. Early studies in which antigen-specific Tr1 cells were induced in vitro by repeated TCR stimulation in the presence of high doses of IL-10 suggested that IL-10 plays an important role in Tr1 cell differentiation [1] . However, it has been recently shown that IL-10 does not play a crucial role during the differentiation of Tr1 cells in vivo [6] . We [7] and others [8] have identified a critical function for IL-27 in the induction of Tr1 cells. Specifically, we found that DC-derived IL-27 is required for the differentiation of IL-10-secreting Tr1 cells, this process is amplified by TGF-b [6, 7] .
Although the generation of Tr1 cells potentially constitutes a new therapeutic approach for immune-mediated diseases, methods for the induction of Tr1 cells in vivo are still missing. Here we report that nasal anti-CD3 triggers the differentiation of suppressive Tr1 cells by a mechanism dependent on the production of IL-27 by upper airway-resident DCs. Furthermore, the generation of Tr1 cells in vivo is controlled by AHR and c-Maf in T cells, and the autocrine effects of IL-21. Thus, nasally administered anti-CD3 might constitute a new approach for the therapeutic induction of Tr1 cells.
Results

Nasal administration of anti-CD3 induces suppressive Tr1 cells
We used tiger mice [9] carrying a green fluorescent reporter (GFP) reporter inserted immediately before the polyadenylation site of the il10 gene to investigate the effect of nasal administration of anti-CD3 on CD4+ IL-10+ T cells. We found that the frequency of CD4+CD25-GFP(IL-10)+ cells was upregulated following nasal treatment with anti-CD3 ( Figure 1A) . Upon activation with anti-CD3 in vitro, FACS sorted CD4+CD25-GFP(IL-10)+ T cells secreted IL-10 and IFN-c ( Figure 1B) . This cytokine pattern is consistent with a Tr1 cell phenotype [10] , and was not seen when CD4+CD25-GFP(IL-10)-naive T cells or CD4+CD25+GFP(IL-10)-T cells were sorted from anti-CD3 treated mice and activated in vitro ( Figure 1B) .
We have previously shown that the suppressive T cells induced by the oral administration of anti-CD3 are characterized by the expression of membrane-bound TGF-b (LAP). In accordance with our previous observations, we found that the CD4+CD25-GFP(IL-10)+ T cells induced by the nasal administration of anti-CD3 were mostly LAP+ (Figure 1c) .
We next studied the suppressive activity of the CD4+CD25-GFP(IL-10)+ T cells induced by nasal treatment with anti-CD3. We found that CD4+CD25-GFP(IL-10)+ T cells isolated from anti-CD3 treated mice suppressed the proliferation of responder CD4+CD25-GFP-T cells ( Figure 1D ). The suppressive activity of the CD4+CD25-GFP(IL-10)+ T cells induced by the nasal administration of anti-CD3 was mediated by IL-10, because it could be abrogated with IL-10 specific antibodies ( Figure 1D ). Similar results were observed when we analyzed the suppressive activity of CD4+ GFP(IL-10)+ Tr1 cells induced in vitro with IL-27 ( Figure 1D ). Taken together these data demonstrate that nasal anti-CD3 generates suppressive LAP+ Tr1 cells.
IL-27 secreted by upper airway-resident DCs is required for the induction of Tr1 cells by nasal anti-CD3
DCs play an important role in the activation and polarization of T cells in vivo [11] . Indeed, we and others have recently described that DC-derived IL-27 [7, 8] and TGF-b [6, 7] play a critical role for in the differentiation of Tr1 cells. To investigate the role of DCs in the generation of Tr1 cells in vivo, we studied the effect of nasal anti-CD3 on the production of cytokines by CD11c+ and CD11b+ cells in the cervical lymph node (CLN). We found that nasal administration of anti-CD3 induces a unique cytokine profile in CD11c+ DCs, characterized by the expression of IL-10, TGF-b and IL-27 ( Figure 2A ). This profile was not observed in CD11b+ macrophages ( Figure 2B ) or splenic or mesenteric lymph nodederived DCs (not shown).
We thus examined the requirement for upper airway resident DCs in the generation of IL-10-secreting LAP+ Tr1 cells, using transgenic mice in which the CD11c promoter controls the expression of a diphtheria toxin receptor (DTR)-GFP cassette [12] . Nasal administration of diphtheria toxin (DT) led to a significant depletion of CD11c+ DCs in the CLN but not in spleen ( Figure 2C) . Moreover, depletion of CLN resident DCs by nasal DT abolished the generation of the IL-10-secreting CD4+CD25-LAP+ T cells induced by nasal anti-CD3 ( Figure 2D) .
To further investigate the role of DCs in the differentiation of IL-10-secreting Tr1 cells, we co-cultured naïve (CD4+CD25-GFP-) Tiger T cells with CD11c+ DCs or CD11b+ macrophages harvested from the CLN of mice treated with nasal anti-CD3. Coincubation with DCs from mice treated with nasal anti-CD3 upregulated the expression of GFP (IL-10) and LAP in T cells ( Figure 2E ). We then used neutralizing antibodies to IL-27 and/ or TGF-b to investigate the mechanisms of Tr1 induction by DCs taken from anti-CD3 treated mice. We found that the induction of GFP (IL-10) and LAP expression by Tr1 cells in vitro was dependent both on DC-derived IL-27 and TGF-b signaling as neutralizing antibodies to IL-27 and/or TGF-b suppressed the expression of both GFP (IL-10) and LAP by Tr1 cells ( Figure 2F ). Taken together, these findings suggest that local DCs promote the generation of LAP+ Tr1 cells by nasal anti-CD3 via the secretion of IL-27 and TGF-b.
Tr1 cells induced by nasal anti-CD3 express ahr, cmaf, il21 and il21r
The transcription factor c-Maf plays an important role in the regulation of il10 expression [13, 14, 15, 16] . We have recently shown that c-Maf interacts with the transcription factor AHR to control the expression of il10 and the autocrine Tr1 growth factor il21 [17] . AHR and cMAF also cooperate to control the expression of human IL10 [18] . To investigate the molecular mechanisms leading to the differentiation of Tr1 cells in vivo in response to the nasal administration of anti-CD3, we studied the expression of maf, ahr, il21 and il21r; was also analyzed the expression of il10, ifng and foxp3. Naïve T cells and CD4+CD25-GFP(IL-10)+ Tr1 cells were FACS-sorted from tiger mice treated with nasal anti-CD3, Foxp3+ nTregs were isolated from Foxp3 GFP knock-in transgenic mice [19] , and gene expression was analyzed by quantitative PCR. We found that freshly isolated CD4+CD25-GFP(IL-10)+ Tr1 cells induced by treatment with nasal anti-CD3 consistently expressed high levels of il10 and also some ifng, however foxp3 expression was undetectable ( Figure 3A) . Moreover, freshly isolated Tr1 cells from nasal anti-CD3 treated mice expressed significant levels of ahr ( Figure 3B ) and maf ( Figure 3C ) as well as il21 ( Figure 3D ) and il21r ( Figure 3E ). Thus the Tr1 cells induced by treatment with nasal anti-CD3 express the transcription factors AHR, c-Maf, and also the autocrine growth factor IL-21.
AHR signaling and IL-21 mediate the induction of Tr1 cells by nasal anti-CD3
To investigate the role of AHR in the generation of Tr1 cells in vivo we generated tiger mice carrying a mutant AHR protein that shows a reduced affinity for its ligands (Ahr d ) [20] . We thus studied the frequency of Tr1 cells in the CLN following nasal anti-CD3 in tiger and Ahr d /tiger mice. Figure 4A shows that induction of GFP(IL-10)+ Tr1 cells by nasal anti-CD3 is completely abolished in the Ahr d /tiger mice, thus AHR signaling is essential for the generation of Tr1 cells in vivo in response to nasally administered anti-CD3.
IL-21 is an autocrine growth factor for Tr1 cells [21, 22] . We have recently reported that AHR and c-Maf directly control the production of IL-21 during the differentiation of Tr1 cells [17] . Thus, based on the expression of il21 and il21r by Tr1 cells induced in response to the nasal administration of anti-CD3, we investigated the role of IL-21 in the generation of Tr1 cells in vivo. We first studied the effect of treating tiger mice with anti-CD3 coadministered nasally with recombinant IL-21 or vehicle as control. We found that the nasal co-administration of anti-CD3 with recombinant IL-21 led to a significant increase in the generation of Tr1 cells ( Figure 4B ). We then analyzed the induction of Tr1 cells by nasal anti-CD3 in IL-21R 2/2 and wild type mice. We found a significant impairment in the induction of Tr1 cells triggered by nasal anti-CD3 in IL-21R 2/2 mice ( Figure 4C) . Thus, IL-21 plays an important role in the induction of Tr1 cells in vivo as a result of treatment with nasal anti-CD3.
Tr1 cells induced by nasal anti-CD3 in an IL-27-dependent manner control systemic autoimmunity
To investigate the role of IL-27 in the induction of Tr1 cells by nasal anti-CD3, we backcrossed IL-27 receptora-deficient mice onto the lupus prone lpr background (IL-27R2/2/lpr). Figures 5A and 5B show that the generation of LAP+ Tr1 cells following nasal administration of anti-CD3 is dependent on IL-27, as no upregulation of LAP was seen in IL-27R2/2/lpr mice. Concomitant with the deficient generation of LAP+ Tr1 cells, we found that CD4+ T cells from IL-27R2/2/lpr mice given nasal anti-CD3 produced significantly higher amounts of IFN-c and IL-12 upon in vitro stimulation with anti-CD3 ( Figure 5B) .
We next investigated the role of IL-27 and LAP+ Tr1 cells induced by nasal anti-CD3 in the control of systemic autoimmunity. IL-27R2/2/lpr mice developed spontaneous fatal autoimmunity significantly earlier than MRL/lpr mice ( Figure 5C , compare green and black lines). This accelerated development of fatal autoimmunity was associated with a progressive increase in serum IgG autoantibodies to double stranded DNA (dsDNA) ( Figure 5D ). Moreover, nasal anti-CD3 (three 5-day courses of 0.5 mg/day given at alternative weeks) significantly prolonged the survival of MRL/lpr but not of IL-27R2/2/lpr mice ( Figure 5C , compare red and blue lines). Taken together, these data suggests that IL-27 is required for the generation of suppressive LAP+ Tr1 cells following nasal administration of anti-CD3.
To confirm that the lack of protective effect of nasal anti-CD3 in IL-27R2/2/lpr mice is linked to the defective induction of LAP+ Tr1 cells ( Figures 5A and 5B) we performed adoptive transfer experiments. The transfer of CLN CD4+ T cells from wild type mice treated with nasal anti-CD3 protected IL-27R2/2/lpr recipients from the development of fatal autoimmunity ( Figure 5E , compare blue and red lines). This protection was associated with a significant reduction in the production of IgG anti-dsDNA autoantibodies ( Figure 5D ). The suppression of systemic autoimmunity in this adoptive transfer system was dependent on LAP+ Tr1 cells, as protection was reversed by We found similar effects when the recipients of LAP+ Tr1 cells were investigated in terms of autoantibody production ( Figure 5D ) and IFN-c and IL-12 production ( Figure 5F ). Thus, IL-27 mediates the induction of LAP+ suppressive Tr1 cells following the nasal administration of anti-CD3 in the context of ongoing inflammation.
Discussion
Tr1 cells are regulatory T cells that do not express Foxp3 and suppress tissue inflammation, graft-versus-host disease and autoimmunity in an IL-10 dependent manner. IL-27 plays a major role in the differentiation of IL-10-secreting Tr1 cells [7, 23] . Indeed, we have recently demonstrated that IL-27 induces the expression of the transcription factors AHR and c-Maf, which cooperate to control the expression of il10 and of the autocrine Tr1 growth factor il21 [17] . AHR and cMaf also cooperate to control the expression of human Il10 [18] .
Here we show that nasal administration of an anti-CD3 monoclonal antibody induces suppressive Tr1 cells. We found that the induction of Tr1 cells is dependent on local DCs that express IL-27, IL-10 and TGF-b as site-specific depletion of DCs abolishes Tr1 cell generation by nasal anti-CD3. To our knowledge, this is the first demonstration of an essential role of upper airway-resident DCs in the generation of Tr1 cells in vivo.
Accumulating evidence suggests that resident DCs in mucosal tissues possess unique features not shared by DCs in peripheral lymphoid tissues [24] . Most notably is their ability to generate regulatory T cells that suppress airway and gut inflammation in mouse models of asthma [25] and inflammatory bowel disease [26] . In support of these findings, it has been demonstrated that resident DCs in lamina propria and mesenteric lymph nodes are critical for the generation of Foxp3+ regulatory T cells in the gut [27, 28, 29] .
The upper airway mucosal DCs may be controlled by local signals produced by the bronchial and intestinal epithelia. For instance, in co-culture studies it has been shown that products of epithelial cells condition DCs to promote Th2 immunity in an allogeneic response [30] . It is possible that in the face of continuous challenge from environmental antigens, mucosal epithelial cells secrete cytokines that condition DCs modified to promote the differentiation of Tr1 cells. Thus, similar to DCs present in gut-associated lymphoid tissue [31, 32] , we show here that DCs present in the nasal-associated lymphoid tissue also play a physiologic role in the generation of regulatory T cells.
We used the nasal anti-CD3, and the administration of nasal anti-CD3 together with recombinant IL-21 significantly boosts the induction of Tr1 cells. These findings are consistent with our recent in vitro studies [17, 18] , and demonstrate that AHR and Il-21 mediate the induction of Tr1 cells triggered by nasally administered anti-CD3. Moreover, they suggest that recombinant IL-21 can be used as an adjuvant to potentiate the induction of suppressive Tr1 cells by nasally administered anti-CD3.
In summary, our data supports a model in which upon stimulation by nasal anti-CD3, resident DCs conditioned by the nasal epithelia secrete IL-27, which promotes the differentiation of Tr1 cells. IL-27R ligation triggers the synthesis of AHR and c-MAF, which then bind and transactivate the il10 and il21 promoters [17, 18] . Finally, IL-21 acts in an autocrine fashion to further upregulate cMAF expression thus expands Tr1 cells in vivo [13, 17, 22] (and fig.6 ). Our results identify a previously unknown function of mucosal DCs in the upper airways and demonstrate that nasal anti-CD3 is a unique approach to generate functional suppressive Tr1 cells in vivo that control ongoing autoimmunity. These findings identify nasal anti-CD3 as a novel therapeutic approach for the treatment of autoimmune diseases. /tiger mice were bred and maintained at our facility at the Harvard Institutes of Medicine. Only female mice were used in lupus studies. All mice were housed in specific pathogen-free environment according to the animal protocol guidelines of the Committee on Animals of Harvard Medical School (Protocol No. 02683), which also approved the experiments.
Materials and Methods
Mice
Antibodies, antigens and nasal treatment
Antibodies specific to CD3 (145-2c11) and CD28 (37.51) (BD Biosciences, CA, USA) were used to stimulate T cells in vitro.
Neutralizing anti-mouse IL-10 (JES5-2A5), TGF-b (1D11), IL-4 (11B11), IL-12 (C17.8), IFN-c (R46A2) or relevant isotype control antibodies were purchased from BioXCell, NH, USA. Neutralizing anti-mouse IL-27p28 and IL-21 antibody and mouse recombinant IL-4, IL-6, IL-12, IL-21 and TGF-b was purchased from R&D Systems, MN, USA. Fluorescent anti-mouse antibodies used in flow cytometry were CD4-specific (H129.19), CD25-specific (PC61) and IL-10 (JES5-16E3) (BD Biosciences). For Fcc receptor blocking we used CD16/CD32-specific antibody (all from BD Biosciences). Anti-mouse LAP monoclonal antibody (16B4) was a kind gift from Taka Oida (Center for Neurologic Disease). Anti-mouse Foxp3 (FJK-16s) antibody was purchased from Ebiosciences, CA, USA. In studies of Tr1 cell generation in vivo, mice were nasally treated with 5 consecutive doses of 0.5 mg hamster IgG CD3-specific antibody (clone 145-2C11) or hamster IgG control antibody (BioXCell) dissolved in PBS. Diphtheria toxin was purchased from Sigma-Aldrich. LPS and FLT3 ligand were purchased from R&D Systems.
T cell proliferation
Cells were cultured in triplicates at 1.5610 6 /ml in the presence of various amounts of antibodies or alone in 96-well round bottom microtiter plates (Corning, NY, USA) for 96 hrs at 37uc with 5% CO 2 in a humid incubator. CD4 + T cells were separated from murine lymphoid organs using MACS CD4 purification kit (Miltenyi Biotec). The purity of selected cells was checked by flow cytometry. In all experiments, selection efficiency was over 90%. For cell sorting CD4 + T cells or whole lymphocytes were stained with fluorescent anti-mouse LAP, CD4 and CD25 monoclonal antibodies (all at 0.5 mg per million cells). CD4+ CD25-or + LAPor + GFP-or + T cells were sorted using a FACSVantage SE (BD Biosciences). The purity of each population was .95% by flow cytometric analysis. Tr1 and Th subset in vitro differentiation was carried out in the present of plate bound anti-CD3 and anti-CD28 and relevant cytokine for 48 hrs followed by passage and 2 additional rounds of 48 hr culture. Tissue culture medium was RPMI-1640 with 4.5 g/L glucose and L-Glutamine (BioWhittaker, MD, USA) supplemented with 2% penicillin and streptomycin (BioWhittaker) and 1% fetal calf serum. Cultures were pulsed with 0.25 mci tritiated thymidine ( 
Immunofluorescent staining
Frozen sections of cervical lymph node or spleen (5 mM) were air dried from 280uc for 30 mins and then fixed in 100% alcohol for 1 min. Sections were washed twice with PBS and non-specific binding sites were blocked with 10% normal rat serum in PBS for 1 hr at RT. Following 2 further washes with PBS, tissue sections were stained with Toprol-3 (Invitrogen, CA, USA). Tissues sections were analyzed by confocal microscopy.
Cytokine detection
The level of cytokines produced in vitro by cell cultures was determined using BD OptEIA ELISA and reagent set (BD Biosciences). Samples were tested in triplicate using the manufacturer's recommended assay procedure. Cell culture supernatant was harvested at different time points (48 hrs for IL-10; 96 hrs for IL-2, IL-5, IL-12 and IFN-c) for the detection of cytokines.
Flow cytometry
Cells were washed (1200 RPM, 5 mins at 4uc) with PBS containing 2% bovine serum albumin in PBS (PBS/BSA, BioWhittaker). Fcc receptors were blocked by incubation with anti-CD16/CD32 antibody for 30 mins at 4uc. Cells were washed twice before being stained with fluorescent anti-mouse cell surface molecule antibodies (1 mg/10 6 cells/test) or relevant IC antibody for 30 min at 4uc in dark. After staining, cells were washed again with PBS/BSA before flow cytometry (FACScan TM , Becton Dickson, NJ, USA). For intracellular staining, cells (10610 6 cells/ml) in culture medium containing 1 ml GolgiSTOP (BD Biosciences) were stimulated with PMA (50 ng/ml) and ionomycin (1000 ng/ml) for 4 hrs at 37uc with 5% CO 2 in a humid incubator. After incubation cells were fixed and permeabilized before being stained. All FACs data was analyzed using FlowJo software (TreeStar).
Serum ELISA Autoantibodies were measured as described previously (14) . Briefly, double stranded DNA (dsDNA) was used at 20 mg/ml. For the detection of total IgG, 50 ml/well of HRP-conjugated rat antimouse antibody (BD Biosciences) at 0.001 mg/ml was added and incubated at 37uc for 1 hr.
Quantitative RTPCR
RNA was extracted from FACS-sorted cells or in vitro differentiated cells using RNAeasy columns (Qiagen, CA, USA). cDNA was transcribed as recommended (Applied Biosystems, CA, USA). The amount of cDNA was measured and equal amount of cDNA from samples was used for quantitative RTPCR. All primer/ probe mixtures were obtained from Applied Biosystems. Taqman analysis was performed on AB 7500 Fast System (Applied Biosystems). Gene expression was normalized to b-actin expression.
Adoptive transfer
To test the in vivo regulatory function of LAP+ T cells we transferred freshly isolated whole CD4 + or CD4 + T cells depleted of LAP+ cells from nasal anti-CD3 treated MRL/lpr donors to 4-wk old IL-27 2/2 /lpr recipients. Each recipient received 1610 6 T cells intravenously. We followed the recipients for 40 weeks and recorded their survival rate. Statistical analysis Statistical differences in cell proliferation and cytokine levels were derived from 2-way ANNOVA test. We used Students't-test on circulating IgG levels. The Wilcoxon rank sum test was used for all pair-wise group comparisons. A P value less than 0.05 is considered significant.
